KR102189409B1 - 암배아성 항원-관련 세포 부착 분자 (ｃｅａｃａｍ)에 대한 항체 - Google Patents

암배아성 항원-관련 세포 부착 분자 (ｃｅａｃａｍ)에 대한 항체 Download PDF

Info

Publication number
KR102189409B1
KR102189409B1 KR1020147010511A KR20147010511A KR102189409B1 KR 102189409 B1 KR102189409 B1 KR 102189409B1 KR 1020147010511 A KR1020147010511 A KR 1020147010511A KR 20147010511 A KR20147010511 A KR 20147010511A KR 102189409 B1 KR102189409 B1 KR 102189409B1
Authority
KR
South Korea
Prior art keywords
seq
delete delete
antibody
set forth
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147010511A
Other languages
English (en)
Korean (ko)
Other versions
KR20140069206A (ko
Inventor
갈 마르켈
테힐라 벤 모세
야이르 사피어
일라나 만델
제이콥 샤흐터
로나 오르텐베르크
Original Assignee
텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드．
씨씨에이엠 바이오세라퓨틱스 리미티드.
라모트 앳 텔-아비브 유니버시티 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드．, 씨씨에이엠 바이오세라퓨틱스 리미티드., 라모트 앳 텔-아비브 유니버시티 리미티드 filed Critical 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드．
Publication of KR20140069206A publication Critical patent/KR20140069206A/ko
Application granted granted Critical
Publication of KR102189409B1 publication Critical patent/KR102189409B1/ko
Assigned to 페임웨이브 리미티드 reassignment 페임웨이브 리미티드 권리지분의 전부이전등록 Assignors: 씨씨에이엠 바이오세라퓨틱스 리미티드.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
KR1020147010511A 2011-10-11 2012-10-10 암배아성 항원-관련 세포 부착 분자 (ｃｅａｃａｍ)에 대한 항체 Active KR102189409B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IL2011/000808 WO2013054320A1 (en) 2011-10-11 2011-10-11 Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
ILPCT/IL2011/000808 2011-10-11
PCT/IL2012/050402 WO2013054331A1 (en) 2011-10-11 2012-10-10 Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)

Publications (2)

Publication Number Publication Date
KR20140069206A KR20140069206A (ko) 2014-06-09
KR102189409B1 true KR102189409B1 (ko) 2020-12-14

Family

ID=48081453

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147010511A Active KR102189409B1 (ko) 2011-10-11 2012-10-10 암배아성 항원-관련 세포 부착 분자 (ｃｅａｃａｍ)에 대한 항체

Country Status (15)

Country Link
US (3) US9771431B2 (https=)
EP (2) EP3360899B1 (https=)
JP (1) JP6170926B2 (https=)
KR (1) KR102189409B1 (https=)
CN (1) CN103987729B (https=)
AU (1) AU2012322272C1 (https=)
BR (1) BR112014008893B1 (https=)
CA (1) CA2851762C (https=)
ES (2) ES2942314T3 (https=)
IL (1) IL231931B (https=)
IN (1) IN2014MN00873A (https=)
LT (1) LT2744829T (https=)
PL (2) PL3360899T3 (https=)
RU (1) RU2650869C2 (https=)
WO (2) WO2013054320A1 (https=)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063424A2 (en) * 2005-06-09 2007-06-07 Gal Markel The modulation of immunity and ceacam1 activity
KR20180077322A (ko) * 2009-04-30 2018-07-06 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드． 항-ｃｅａｃａｍ1 항체들과 이를 이용하는 방법들
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
WO2015075710A1 (en) * 2013-11-25 2015-05-28 Ccam Biotherapeutics Ltd. Compositions comprising anti-ceacam1 antibodies, lymphocyte activating agents and activated lymphocytes for cancer therapy
PL3763387T3 (pl) * 2013-11-25 2024-07-29 Famewave Ltd Kompozycje zawierające przeciwciała anty-ceacam1 i anty-pd do terapii nowotworu
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
EP3087099A4 (en) * 2013-12-23 2017-07-19 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
WO2015101996A1 (en) * 2014-01-02 2015-07-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
US10550196B2 (en) * 2014-04-27 2020-02-04 Famewave Ltd. Humanized antibodies against CEACAM1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US9753036B2 (en) * 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
WO2016120331A1 (de) 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CA2992551A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
RU2018126297A (ru) 2015-12-18 2020-01-22 Новартис Аг Антитела, нацеленные на cd32b, и способы их применения
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
EP4643874A3 (en) 2015-12-22 2026-02-11 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
CN107345969A (zh) * 2016-05-05 2017-11-14 中国医学科学院基础医学研究所 包含afp、gp73和ceacam1的血清标记物在诊断肝脏疾病中的用途
CN107345968A (zh) * 2016-05-05 2017-11-14 中国医学科学院基础医学研究所 Cecam1蛋白作为血清标记物在诊断肝脏疾病中的用途
EP3487878A4 (en) 2016-07-20 2020-03-25 University of Utah Research Foundation CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
WO2018019380A1 (de) * 2016-07-28 2018-02-01 Universität Duisburg-Essen Immunstimulatorische anti-ceacam1-antikörper
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
CN110248678A (zh) 2016-12-03 2019-09-17 朱诺治疗学股份有限公司 调节car-t细胞的方法
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
KR102019913B1 (ko) * 2017-03-24 2019-09-09 재단법인 목암생명과학연구소 항-ceacam1 항체 및 이의 용도
CN110475788A (zh) 2017-03-24 2019-11-19 财团法人牧岩生命科学研究所 抗ceacam1抗体及其应用
KR102325944B1 (ko) * 2017-11-30 2021-11-12 재단법인 목암생명과학연구소 항-ceacam1 항체 및 이의 용도
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
JP2020526194A (ja) 2017-06-29 2020-08-31 ジュノー セラピューティクス インコーポレイテッド 免疫療法薬と関連する毒性を評価するためのマウスモデル
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
JP7383620B2 (ja) 2018-01-31 2023-11-20 セルジーン コーポレイション 養子細胞療法およびチェックポイント阻害剤を使用する併用療法
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CA3098815A1 (en) * 2018-05-09 2019-11-14 Good T Cells, Inc. Epitope of regulatory t cell surface antigen and antibody specifically binding thereto
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
CN110684107B (zh) * 2018-07-06 2021-03-23 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(MGd1)及其用途
CN110684108B (zh) * 2018-07-06 2021-06-04 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(CEA37)及其用途
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
MA54078A (fr) 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
EP3873937A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
IL283218B2 (en) 2018-11-16 2025-11-01 Juno Therapeutics Inc Dosing methods of engineered T cells for the treatment of malignant B cells
PT3886875T (pt) 2018-11-30 2024-06-27 Juno Therapeutics Inc Métodos para tratamento utilizando terapia celular adotiva
EP3906261A4 (en) * 2018-12-07 2022-12-21 The Brigham And Women's Hospital, Inc. HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES
JP2022514615A (ja) 2018-12-20 2022-02-14 アルバート アインシュタイン カレッジ オブ メディスン ヒト免疫チェックポイントＣＥＡＣＡＭ１（ＣＤ６６ａ）に対するアンタゴニスト抗体及びその製剤、キット並びに使用方法
KR102166982B1 (ko) * 2019-01-24 2020-10-16 가톨릭대학교 산학협력단 간암에서 CEACAM1 및 EpCAM의 상관관계 및 이를 이용한 간암 치료효과에 대한 정보를 제공하는 방법
SG11202107976SA (en) 2019-01-29 2021-08-30 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
AU2020289301B2 (en) * 2019-06-04 2025-07-24 Biotheus Inc. CEACAM5-resistant monoclonal antibody and preparation method thereof and use thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP2023501387A (ja) * 2019-11-07 2023-01-18 グリーン・クロス・コーポレイション Ｃｅａｃａｍ１の立体エピトープ、及びｃｅａｃａｍ１の立体エピトープに特異的に結合する抗ｃｅａｃａｍ１抗体又はその断片
EP4065157A1 (en) 2019-11-26 2022-10-05 Novartis AG Cd19 and cd22 chimeric antigen receptors and uses thereof
JP2023522857A (ja) 2020-04-10 2023-06-01 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
EP3909601A1 (en) * 2020-05-11 2021-11-17 LeukoCom GmbH A novel antibody binding specifically to human ceacam1/3/5 and use thereof
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
CN111675750B (zh) * 2020-06-11 2022-08-30 中国药科大学 针对癌胚抗原相关黏附分子ceacam的肿瘤靶向肽及其应用
KR20230035576A (ko) 2020-07-07 2023-03-14 비온테크 에스이 Hpv 양성 암 치료용 rna
CN113278074B (zh) * 2020-08-04 2022-03-29 中山大学附属第五医院 抗ceacam5纳米抗体
CA3188867A1 (en) 2020-08-20 2022-02-24 Xueyin Wang Compositions and methods for treating ceacam positive cancers
IL300500A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Preparations and methods for the treatment of mesothelin positive cancer
WO2022040470A1 (en) * 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
US12037409B2 (en) * 2020-08-21 2024-07-16 Shanghai GenBase Biotechnology Co., Ltd. Antibody specifically bound to glycosylated CEACAM5
WO2022041745A1 (zh) * 2020-08-28 2022-03-03 安源医药科技（上海）有限公司 针对SARS-CoV-2冠状病毒S蛋白的抗体及其用途
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
CN112457402B (zh) * 2020-10-21 2022-08-30 北京纽安博生物技术有限公司 抗ceacam6单域抗体、人源化单域抗体及其融合蛋白和应用
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
US20240083998A1 (en) * 2021-01-04 2024-03-14 City Of Hope Prevention and treatment of steroid-resistant or gut graft-versus-host disease (gvhd)
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
JP2025525937A (ja) 2022-08-05 2025-08-07 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
WO2024034580A1 (ja) * 2022-08-08 2024-02-15 株式会社先端生命科学研究所 Ｃｅａｃａｍ１を検出する方法
EP4569002A2 (en) 2022-08-10 2025-06-18 Merck Sharp & Dohme LLC Proteins binding nkg2d, cd16, and ceacam5
EP4615871A1 (en) * 2022-11-10 2025-09-17 FameWave Ltd. Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
KR20250135354A (ko) 2022-12-13 2025-09-12 주노 쎄러퓨티크스 인코퍼레이티드 Baff-r 및 cd19에 특이적인 키메라 항원 수용체 및 그의 방법 및 용도
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
WO2024165403A1 (en) 2023-02-06 2024-08-15 Philogen S.P.A. Anti-cea antibodies
WO2024213096A1 (en) * 2023-04-13 2024-10-17 Suzhou Neologics Bioscience Co., Ltd. Ceacam1-targeting antibodies and uses thereof
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190600A1 (en) 2002-04-05 2003-10-09 Dana-Faber Cancer Institute Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
WO2010125571A1 (en) 2009-04-30 2010-11-04 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anti ceacam1 antibodies and methods of using same

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6022958A (en) 1986-08-13 2000-02-08 Bayer Corporation cDNAs coding for members of the carcinoembryonic antigen family
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP0787185A2 (en) 1994-10-20 1997-08-06 MorphoSys AG Targeted hetero-association of recombinant proteins to multi-functional complexes
GB9421405D0 (en) 1994-10-21 1994-12-07 Dow Chemical Co Low voc laminating formulations
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
ES2246567T3 (es) 1998-04-15 2006-02-16 Brigham & Womens Hospital Composiciones para receptores inhibidores de celulas t y usos de las mismas.
DE19852804C1 (de) 1998-11-16 1999-12-23 Christoph Wagener Beeinflussung der Angiogenese durch CD66a
AU6940700A (en) 1999-08-26 2001-03-19 Amy P. N Skubitz Peptides capable of modulating the function of cd66 (ceacam) family members
DE10016877A1 (de) 2000-04-05 2001-10-18 Scintec Diagnostics Gmbh Zug (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung
SE0002835D0 (sv) 2000-08-07 2000-08-07 Karolinska Innovations Ab Method and kit for production of monoclonal antibodies
EP1472276A4 (en) 2001-02-28 2007-05-09 Keith M Skubitz PEPTIDES OF SMALL SIZE CAPACITY TO MODULATE THE FUNCTION OF THE MEMBERS OF THE FAMILY OF CD66 (CEACAM)
US20030022292A1 (en) 2001-06-07 2003-01-30 Gray-Owen Scott D. Ligation of CEACAM1
US20060058257A1 (en) 2001-08-03 2006-03-16 Christoph Wagener Influencing angiogenesis using CD66a
US20050107324A1 (en) 2003-07-12 2005-05-19 Bennett C. F. Modulation of CEACAM1 expression
US20030211477A1 (en) 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
CU23228A1 (en) 2002-04-29 2007-09-26 Ct Ingenieria Genetica Biotech FRAGMENTS OF SPECIFIC ANTIBODIES FOR THE HUMAN CARCINOEMBRIONARY ANTIGEN (CEA) SEQUENCES OF ITS VARIABLE REGIONS AND VECTORS FOR THE MICROBIAL EXPRESSION OF THE SAME
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
KR20050073488A (ko) 2002-10-08 2005-07-13 이뮤노메딕스, 인코오포레이티드 Ⅲ종 항-ｃｅａ 단클론 항체들 및 치료제들을 이용한 조합치료법
CN101972478B (zh) 2002-10-08 2012-10-31 免疫医疗公司 抗体治疗
WO2005050200A2 (en) 2003-11-13 2005-06-02 Genentech, Inc. Screening assays and methods of tumor treatment
CA2572289A1 (en) * 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses
WO2007063424A2 (en) 2005-06-09 2007-06-07 Gal Markel The modulation of immunity and ceacam1 activity
US20090226444A1 (en) * 2005-12-21 2009-09-10 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
JP5399712B2 (ja) 2005-12-21 2014-01-29 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬組成物
WO2008029271A2 (en) 2006-02-27 2008-03-13 Gal Markel Ceacam based antibacterial agents
CN103864893B (zh) * 2007-07-27 2017-01-04 伊玛提克斯生物技术有限公司 免疫疗法的免疫抗原表位
WO2009141679A2 (en) 2007-11-05 2009-11-26 Gal Markel Ceacam1 based point-of-care cancer diagnostic
WO2009090953A1 (ja) 2008-01-17 2009-07-23 Nec Corporation 無線通信端末、方法、プログラム、記録媒体、および無線通信システム
ES2753986T3 (es) 2009-07-21 2020-04-15 Tel Hashomer Medical Res Infrastructure & Services Ltd Un método de diagnóstico de cáncer
KR101528013B1 (ko) * 2009-08-31 2015-06-16 로슈 글리카트 아게 친화성-성숙된 인간화된 항-ｃｅａ 단일클론 항체
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
US8256790B2 (en) 2010-05-26 2012-09-04 William Olen Fortner Adjustable receiver hitch system
CN104011925A (zh) 2011-12-27 2014-08-27 株式会社Lg化学 锂二次电池及其制备方法
HK1213788A1 (zh) 2012-10-12 2016-07-15 布里格姆及妇女医院股份有限公司 免疫應答的增强

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190600A1 (en) 2002-04-05 2003-10-09 Dana-Faber Cancer Institute Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
WO2010125571A1 (en) 2009-04-30 2010-11-04 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anti ceacam1 antibodies and methods of using same

Also Published As

Publication number Publication date
PL2744829T3 (pl) 2018-06-29
BR112014008893A2 (pt) 2017-11-28
KR20140069206A (ko) 2014-06-09
BR112014008893B1 (pt) 2022-04-26
US11891453B2 (en) 2024-02-06
AU2012322272A1 (en) 2014-04-10
WO2013054331A8 (en) 2014-04-10
WO2013054331A1 (en) 2013-04-18
US20170355781A1 (en) 2017-12-14
IL231931A0 (en) 2014-05-28
JP6170926B2 (ja) 2017-07-26
RU2014118773A (ru) 2015-11-20
CA2851762C (en) 2021-11-30
EP3360899B1 (en) 2023-01-25
EP2744829A4 (en) 2015-06-03
WO2013054320A1 (en) 2013-04-18
CN103987729A (zh) 2014-08-13
US20140271618A1 (en) 2014-09-18
EP2744829A1 (en) 2014-06-25
HK1199646A1 (en) 2015-07-10
JP2015502138A (ja) 2015-01-22
EP2744829B1 (en) 2017-12-13
AU2012322272B2 (en) 2017-08-17
IL231931B (en) 2019-06-30
ES2661488T3 (es) 2018-04-02
EP3360899A1 (en) 2018-08-15
US9771431B2 (en) 2017-09-26
PL3360899T3 (pl) 2023-07-10
LT2744829T (lt) 2018-03-26
AU2012322272C1 (en) 2017-11-02
ES2942314T3 (es) 2023-05-31
CA2851762A1 (en) 2013-04-18
RU2650869C2 (ru) 2018-04-17
CN103987729B (zh) 2017-05-31
US20210070884A1 (en) 2021-03-11
IN2014MN00873A (https=) 2015-07-03

Similar Documents

Publication Publication Date Title
US11891453B2 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
CN108368174B (zh) 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
CN108137691B (zh) 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
CN106573977B (zh) 针对ceacam1的人源化抗体
KR20210117277A (ko) 인간 넥틴-2에 특이적인 항체
EP3440111B1 (en) Anti-vegfr-1 antibodies and uses thereof
RU2820275C2 (ru) Антитела, специфичные в отношении нектина-2 человека
HK1199646B (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
HK40060175B (zh) 特异性针对人类连接蛋白-2的抗体
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000